ROCKET PHARMACEUTICALS, INC.

RCKTSEC EDGAR

Pharmaceutical Preparations(DE)CIK: 1281895

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue from Contract with Customer, Excluding Assessed Tax	$0.00	$0.00	$0.00	$0.00	$0.00
Research and Development Expense	$171.2M	$165.6M	$125.5M	$105.4M	$57.9M
Operating Expenses	$273.2M	$224.3M	$167.2M	$134.3M	$76.2M
Operating Income (Loss)	-$273.2M	-$224.3M	-$167.2M	-$134.3M	-$76.2M
Interest Expense	$1.9M	$1.9M	$3.0M	$7.0M	$6.0M
Nonoperating Income (Expense)	—	—	—	-$5.4M	—
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest	-$258.7M	—	—

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Assets	$527.7M	$566.3M	$551.8M	$497.0M	$590.8M
Assets, Current	$378.2M	$378.2M	$364.1M	$392.1M	$487.3M
Cash and Cash Equivalents, at Carrying Value	$163.6M	$55.9M	$140.5M	$232.7M	$297.1M
Liabilities	$64.5M	$73.8M	$62.1M	$42.3M	$87.3M
Liabilities, Current	$40.7M	$48.5M	$39.2M	$22.2M	$32.6M
Accounts Payable, Current	—	—	—	—	—
Stockholders' Equity Attributable to Parent	$492.6M	$454.7M	$503.5M	$307.3M

Concept	FY2025	FY2024	FY2023	FY2022	FY2021
Net Cash Provided by (Used in) Operating Activities	-$209.7M	-$178.1M	-$121.2M	-$74.6M	-$64.7M
Net Cash Provided by (Used in) Investing Activities	$131.7M	-$69.3M	$18.9M	-$96.6M	-$39.0M
Net Cash Provided by (Used in) Financing Activities	$185.7M	$155.3M	$37.7M	$283.0M	$177.8M
Payments to Acquire Property, Plant, and Equipment	$5.9M	$8.4M	$7.6M	$20.6M	$23.3M
Payments for Repurchase of Common Stock	—	—	—	—	$0.00

Access SEC EDGAR data via REST API. Free tier available.

from sec_edgar import SecEdgar

api = SecEdgar("YOUR_KEY")
api.revenue("AAPL", limit=5)